Emeline M. Aviki, MD, MBA, is a nationally recognized leader known for innovations in delivering cancer care, holds two critical roles at NYU Langone’s Perlmutter Cancer Center: she serves as both a gynecologic oncologist who sees and treats patients across Long Island — including in Mineola and Patchogue — and as medical director of network integration and strategy for the cancer center.
As clinical assistant professor in the Department of Obstetrics and Gynecology at NYU Grossman Long Island School of Medicine, Dr. Aviki specializes in radical cytoreductive surgery, robotic surgery, fertility-sparing surgery, risk-reducing surgery, and prescribing chemotherapy for patients with ovarian, endometrial, cervical, vaginal, and vulvar cancers.
That clinical excellence meets strategy acumen in the role of medical director of network integration and strategy, where Dr. Aviki works to advance network expansion, integration, and operations.
Perlmutter Cancer Center has made a series of strategic investments in improving cancer care outcomes for patients who live on Long Island, as well as in Brooklyn and Queens, by bringing world-class cancer specialists and innovative programs to those communities.
She partners with cancer center leadership and with members of the community to fulfill Perlmutter Cancer Center’s mission to provide world-leading cancer care closer to home.
Before joining NYU Langone, Dr. Aviki was nationally recognized for innovation in providing cancer care and was named one of the “40 under 40 in Cancer” by the Association for Value-Based Cancer Care.
At Memorial Sloan Kettering Cancer Center, she founded and led the Affordability Working Group, where she and a multidisciplinary team conducted a three-cycle Plan-Do-Study-Act process to develop, test, and implement a program to refer patients who had cancer and who were in financial need to a hospital-based financial assistance program. In short order, this innovation resulted in hundreds of thousands of dollars in financial aid reaching the patients in need.
Dr. Aviki also led a study examining how dose-specific packaging of oral agents can inflict unnecessary costs on patients and their families.
Dr. Aviki presented the study on lenvatinib, used for treatment of recurrent endometrial cancer, at The Society of Gynecologic Oncology annual meeting. In response, the pharmaceutical company, Eisai US, created an expanded dose-exchange program for all indications and doses of lenvatinib, eliminating the overspending.
Perlmutter Cancer Center at NYU Langone Hospital—Long Island is the only National Cancer Institute–designated Comprehensive Cancer Center with a hospital on Long Island.
It offers a robust portfolio of clinical trials, including phase 1a trials, so that patients have the ability to participate in novel lifesaving treatments in a way that is accessible, affordable, and convenient.
Dr. Aviki received her medical degree and master of business administration from Duke University.
She completed an obstetrics and gynecology residency at the Harvard combined program at Massachusetts General Hospital and Brigham and Women’s Hospital, followed by a gynecologic oncology fellowship at Memorial Sloan Kettering Cancer Center.
She has written more than 70 articles in research publications and is on the editorial board for the Journal of Clinical Oncology, Oncology Practice. Castle Connolly named her a Rising Star in 2022 and 2023 and in its “Top Doctors” series for the New York metro area in 2022 and 2023. Dr. Aviki was recently elected to serve as Secretary-Treasurer of the Society of Gynecologic Oncology, a national society focused on the comprehensive management of gynecologic cancers.
